Functions of Oxysterol-Binding Proteins at Membrane Contact Sites and Their Control by Phosphoinositide Metabolism

Fubito Nakatsu* and Asami Kawasaki

Department of Neurochemistry and Molecular Cell Biology, Niigata University School of Medicine and Graduate School of Medical/Dental Sciences, Niigata, Japan

Lipids must be correctly transported within the cell to the right place at the right time in order to be fully functional. Non-vesicular lipid transport is mediated by so-called lipid transfer proteins (LTPs), which contain a hydrophobic cavity that sequesters lipid molecules. Oxysterol-binding protein (OSBP)-related proteins (ORPs) are a family of LTPs known to harbor lipid ligands, such as cholesterol and phospholipids. ORPs act as a sensor or transporter of those lipid ligands at membrane contact sites (MCSs) where two different cellular membranes are closely apposed. In particular, a characteristic functional property of ORPs is their role as a lipid exchanger. ORPs mediate counter-directional transport of two different lipid ligands at MCSs. Several, but not all, ORPs transport their lipid ligand from the endoplasmic reticulum (ER) in exchange for phosphatidylinositol 4-phosphate (PI4P), the other ligand, on apposed membranes. This ORP-mediated lipid “countertransport” is driven by the concentration gradient of PI4P between membranes, which is generated by its kinases and phosphatases. In this review, we will discuss how ORP function is tightly coupled to metabolism of phosphoinositides such as PI4P. Recent progress on the role of ORP-mediated lipid transport/countertransport at multiple MCSs in cellular functions will be also discussed.

Keywords: ORPs, phosphoinositide, membrane contact site (MCS), lipid transfer protein (LTP), PI4P, phosphatidylserine (PS), cholesterol, lipid countertransport

INTRODUCTION

Lipids have multiple essential roles, including serving as building blocks for cellular membranes, storing energy, and regulating signaling and membrane dynamics/trafficking. In eukaryotes, most, but not all, lipids are synthesized at the endoplasmic reticulum (ER) and then must be correctly delivered to the places where they exert diverse functions (van Meer and de Kroon, 2011; Santos and Preta, 2018). In addition, lipids often move and change their location even during their metabolic or catabolic processes (van Meer et al., 2008). Thus, lipids rely on their transport systems for accomplishing their diverse and complex tasks in biological systems.

Lipids are transported within cells via membrane carriers (vesicles) along secretory and endocytic membrane trafficking pathways (van Meer et al., 2008; Vance, 2014; Stefan et al., 2017). In addition to vesicular transport, lipids are also transported in a vesicle-independent manner...
Non-vesicular lipid transport is mediated by so-called lipid transfer proteins (LTPs) (Holthuis and Menon, 2014; Wong et al., 2019). LTPs contain a hydrophobic cavity that sequesters lipid molecules from aqueous cytosolic environments, and in this way, they mediate lipid transport between cellular membranes (Wong et al., 2017). Although LTPs are technically able to transport lipids to any accessible place by freely moving in the cytosol, they often do so at membrane contact sites (MCSs). MCSs are places where there is close apposition of cellular membranes (generally 10–30 nm, but the distance differs depending on the type of MCSs) (Helle et al., 2013; Eisenberg-Bord et al., 2016; Scorrano et al., 2019). Accumulating evidence indicates that the ER, which is widely distributed throughout the cell, forms MCSs with most of the organelles or the plasma membrane (PM), and these MCSs serve as zones for non-vesicular lipid transport (Phillips and Voeltz, 2015; Wu et al., 2018; Balla et al., 2019; Prinz et al., 2019; Bohnert, 2020). A number of LTPs have been reported to localize at MCSs and, thus, mediate the transport of a variety of lipid ligands (Wong et al., 2017, 2019).

In this review, we provide an overview of recent progress on understanding the role of oxysterol-binding protein (OSBP)-related proteins (ORPs) (Raychaudhuri and Prinz, 2010; Olkkonen, 2015; Pietrangelo and Ridgway, 2018), a large family of LTPs. Particular focus is placed on their lipid transport function at MCSs and their role in cellular processes in mammals. Given that ORP functions are closely coupled to phosphatidylinositol 4-phosphate (PI4P) metabolism, we will begin with background information as well as recent findings on PI4P, followed by ORP family functions, with the overall goal of an in-depth discussion on the physiological significance of lipid transport at MCSs mediated by ORPs and phosphoinositides.

**PHOSPHATIDYLINOSITOL 4-PHOSPHATE**

**Phosphatidylinositol 4-Phosphate Metabolism in the Cell**

Phosphoinositides are a minor group of phospholipids that represent 10–15% of total phospholipids in the cell (Vance, 2014). The inositol ring in their headgroup is exposed to the cytosol, and its 3, 4, or 5 position can be phosphorylated or dephosphorylated to create seven distinct phosphoinositide species (Balla, 2013). Those phosphoinositides are unevenly distributed in the cell (Di Paolo and De Camilli, 2006). For instance, PI(4,5)P₂ is concentrated at the PM, while PI4P, its major precursor, is distributed more widely (see below for details). PI(3,4,5)P₃ is also localized at the PM, but its level transiently increases locally under certain conditions. Such spatial and temporal distribution of each phosphoinositide species, which determines the identity of cellular membranes, is tightly controlled, mostly based on the action of their metabolic phosphoinositide kinases or phosphatases that localize in distinct cellular compartments (Di Paolo and De Camilli, 2006; Balla, 2013).

PI4P, which is mono-phosphorylated at the 4-position of the inositol ring, is one of the most abundant phosphoinositides in eukaryotes. Its de novo synthesis is mediated by phosphatidylinositol 4-kinases (PI4Ks) that phosphorylate phosphatidylinositol (PI), the substrate, at the 4 position of the inositol ring (Balla, 2013). In mammals, there are four PI4Ks: two type III PI4Ks (PI4K3α and PI4K3β) and two type II PI4Ks (PI4K2α and PI4K2β) (Balla and Balla, 2006; Bouri and Nencik, 2015). As a side note, type I PI4K turned out to be PI3K, and thus, no type I PI4Ks exists at present. The cellular distribution of PI4P is primarily determined by the localization as well as the site of action of its responsible kinases. PI4P is mainly distributed at the PM, the Golgi, and endosomes/lysosomes, and those pools of PI4P are synthesized by PI4K3α, PI4K3β, and PI4K2α or PI4K2β, respectively (Figure 1). A pool of PI4P at autophagosomes has also been demonstrated (Figure 1) (Albanesi et al., 2015; Wang et al., 2015; Judith et al., 2019; De Tito et al., 2020).

**Phosphatidylinositol 4-Kinases**

PI4K3α localizes at the PM with the help of other regulatory proteins including EFR3A, EFR3B, TTC7A, TTC7B, FAM126A, FAM126B, and TMEM150A (Nakatsu et al., 2012; Baskin et al., 2015; Bojjireddy et al., 2015; Chung et al., 2015a). Biochemical as well as genetic evidences show that PI4K3α is required for PI4P production at the PM, and other PI4Ks are unable to compensate for this kinase, suggesting a distinct and non-overlapping function of PI4Ks (Nakatsu et al., 2012). PI4K3β localizes at the Golgi where it produces PI4P (Wong et al., 1997; Antonietta De Matteis et al., 2005). Several proteins, including Arf1 (Godi et al., 1999), ACBD3 (Sasaki et al., 2011) and PKD (Hausser et al., 2005), are reported to support its Golgi localization and function. Both type II PI4Ks, PI4K2α and PI4K2β, localize at endosomes or late endosomes/lysosomes and produce a pool of PI4P at those membranes (Balla and Balla, 2006). PI4K2α and PI4K2β localize at the endosomal membranes via palmitoylation (Balla et al., 2002; Barylko et al., 2009; Lu et al., 2012). PI4K2α has been shown to localize and generate a pool of PI4P at the trans-Golgi network (TGN) as well (Wang et al., 2003). PI4K2α and PI4K3β have been shown to associate with the autophagosomes, where they contribute to the generation of the pool of PI4P (Albanesi et al., 2015; Wang et al., 2015; Judith et al., 2019; De Tito et al., 2020).

PI4Ks were reported to localize in the nucleus and generate a pool of PI4P (reviewed in Chen et al., 2020). Recent findings have revealed the presence of PI, the precursor of PI4P, at the outer membrane of the mitochondria (Pemberton et al., 2020b; Zewe et al., 2020). In addition, functional involvement and localization of the TGN-derived vesicles containing PI4P, which is synthesized by PI4K3β, have been observed at the ER–mitochondria MCSs (Nagashima et al., 2020). However, no direct evidence for the existence of PI4P or PI4Ks at the mitochondria has been reported.

**Phosphatidylinositol 4-Phosphate Phosphatases**

Metabolic degradation of PI4P (i.e., dephosphorylation) is controlled by the suppressor of actin (Sac)-domain containing...
FIGURE 1 | Phosphatidylinositol 4-phosphate (PI4P) metabolism in the cell. (A) De novo PI4P synthesis is catalyzed by PI 4-kinases that phosphorylate phosphatidylinositol (PI) at the D4 position of the inositol ring. Dephosphorylation of PI4P is mediated by 4-phosphatases. (B) Distribution of PI4P and its kinases and phosphatases in the mammalian cell. PI4P is synthesized at the plasma membrane (PM), Golgi, and endosomes/lysosomes by PI4K3α, PI4K3β, and PI4K2α/β, respectively. PI4K2α and possibly PI4K3β as well contribute to the generation of a pool of PI4P at autophagosomes. Metabolic degradation of PI4P is mediated by PI4P phosphatases such as Sac1 and Sac2/INPP5F. PI, phosphatidylinositol; PI4P, phosphatidylinositol 4-phosphate; TGN, trans-Golgi network.

phosphoinositide phosphatase family. The Sac phosphatase domain family in mammals consists of five members including Sac1, Sac2/INPP5F, Sac3/Fig4, Synaptojanin1, and Synaptojanin2, which all contain the Sac domain, a phosphoinositide phosphatase domain (Hsu and Mao, 2013). Sac1 is the major phosphatase that controls PI4P metabolism in the cell (Del Bel and Brill, 2018), although it dephosphorylates PI3P and PI(3,5)P2 in addition to PI4P (Guo et al., 1999; Nemoto et al., 2001). Sac1 is a type II transmembrane protein that localizes at the ER, but translocates to Golgi via COPII-mediated transport at the nutrient-limiting condition (Blagoveshchenskaya et al., 2008). Several pieces of evidence suggest that Sac1 dephosphorylates PI4P on the ER membranes and that it is transported from other membranes to the ER via MCSs (see below). This “in cis” action of Sac1 keeps the levels of PI4P low at the ER and, thus, critically contributes to the ORP-mediated lipid countertransport by creating a concentration gradient of this lipid between the ER and other membranes, which will be described later in detail. However, the “in trans” action of Sac1, in which it dephosphorylates PI4P on the PM or the Golgi membranes, was also reported (Stefan et al., 2011; Dickson et al., 2016; Venditti et al., 2019a).

Sac2/INPP5F and synaptojanins contribute to the metabolism of a pool of PI4P in the endocytic pathway. Synaptojanins have a 5-phosphatase domain that dephosphorylates PI(4,5)P2 in addition to the Sac1 domain (McPherson et al., 1996). The well-known site of action of synaptojanins is at the clathrin-coated pits. Synaptojanins are recruited to the clathrin-coated pits where they sequentially dephosphorylate PI(4,5)P2-PI4P-PI via 5-phosphatase and 4-phosphatase enzymatic activities (Mani et al., 2007; Cao et al., 2017). Likewise, Sac2/INPP5F is also recruited to the late phase of endocytic structures (Hsu et al., 2015; Nakatsu et al., 2015; Levin et al., 2017). Sac2/INPP5F interacts with OCRL, a 5-phosphatase that is also recruited to clathrin-coated pits (Pirruccello and De Camilli, 2012). OCRL has a 5-phosphatase domain but lacks a 4-phosphatase domain. Thus, OCRL dephosphorylates PI(4,5)P2 to PI4P, and then Sac2/INPP5F dephosphorylates PI4P to PI during endocytosis. Thus, OCRL and Sac2/INPP5F function as a split-synaptojanin to cooperatively dephosphorylate PI(4,5)P2 to PI (Nakatsu et al., 2015). A recent finding suggests a role of Sac2/INPP5F in the exocytic pathway (Nguyen et al., 2019).

ORP FAMILY PROTEINS

ORPs are a family of LTPs that are highly conserved in eukaryotes (Ollkonen, 2015; Pietrangelo and Ridgway, 2018). Seven members in yeast and 12 members in humans have been identified, suggesting a requirement for multiple players that cover diverse cellular functions (Lehto et al., 2001; Raychaudhuri and Prinz, 2010). The 12 known ORPs in mammals are subdivided into six groups according to their sequence homology and domain organization: OSBP and ORP4 in group I, ORP1 and ORP2 in group II, ORP3, ORP6, and ORP7 in group III, ORP5 and ORP8 in group IV, ORP9 in group V, and ORP10 and ORP11 in group VI (Figure 2). Mounting evidence demonstrates that ORPs regulate a variety of cellular functions including, but not limited to, lipid transport, membrane/organelle trafficking, and signaling.

Functional Domains in ORPs

Oxysterol-Binding Protein-Related Domain

Several domains or motifs are conserved in this family. One common feature of the ORP family members is the lipid-harboring domain called oxysterol-binding protein-related domain (ORD). Originally, OSBP, the first identified member of the ORP family, was identified as a cytosolic OSBP (Taylor et al., 1984). This study led to the discovery of the larger ORP family that commonly has an ORD as a lipid-transfer
that the tandem histidine residues are responsible for the binding to the head group of PI4P, the ORP family might be structurally adapted to harbor PI4P as a common ligand (de Saint-Jean et al., 2011; Tong et al., 2013).

Membrane Targeting Domains/Motif
Most ORPs possess a Pleckstrin homology (PH) domain (Lemmon, 2008) in their N-terminal portion that mediates membrane association. Many of them have been characterized to have a high affinity to phosphoinositides such as PI4P and/or PI(4,5)P2. Since phosphoinositides are the critical determinants of cellular membrane identity (Di Paolo and De Camilli, 2006), recognition of such lipids by a PH domain is a key process for localization and, hence, MCS formation by ORPs. They also often have another determinant that associates with the ER. The FFAT (two phenylalanines in acidic tract) motif is recognized by ER-resident membrane protein vesicle-associated membrane protein (VAMP)-associated protein A or B (VAPA or VAPB) with their major sperm protein (MSP) domain (Loewen et al., 2003). The FFAT motif is present in many other LTPs that function at MCSs (Murphy and Levine, 2016). Another ER-associating structure is the membrane spanning domain in ORP5 and ORP8, which enables ER localization on its own. These ER-anchoring determinants help bridge the ER and target membranes at MCSs, where they mediate lipid transfer functions.

Lipid Transfer Regulation by ORPs
A major function of ORPs is to transfer their lipid ligands between cellular membranes (Raychaudhuri and Prinz, 2010). Their lipid transfer activity has been extensively studied in vitro (Wong et al., 2017). Purified ORD protein has been shown to extract lipids from artificial liposomal membranes. When mixed with two different liposomes, the ORD is able to transfer lipids from one liposome to another (Pietrangelo and Ridgway, 2018). In the cellular context, most, but not all, ORPs have been shown to mediate lipid transfer between cellular membranes. The mode of lipid transfer is either shuttling between two different membrane compartments that have certain distance or direct transfer at MCSs (Wong et al., 2019).

An interesting nature of ORPs is their lipid exchange activity. OSBP or its yeast counterpart Osh4/Kes1 was initially demonstrated to be a sterol transfer protein (Raychaudhuri et al., 2006; Ngo and Ridgway, 2009). Indeed, they transfer cholesterol (or ergosterol in yeast) between membranes both in vitro and in live yeast. However, de Saint-Jean et al. (2011) elegantly demonstrated that Osh4/Kes1 transfers not only sterol, but also PI4P via its ORD. Its crystal structure showed that the ORD of Osh4/Kes1 accommodates either sterols (cholesterol, ergosterol, and oxysterols) or PI4P. An interesting point was that Osh4/Kes1 mediates exchange of sterol and PI4P between two different liposomes containing either lipid. Subsequently, the same group extended this idea to demonstrate that OSBP mediates countertransport of PI4P and cholesterol at MCSs between the ER and Golgi (Mesmin et al., 2013). ORP5 and ORP8 have also been demonstrated to mediate countertransport of PI4P and PS at ER–PM MCSs.
PI4P-driven lipid countertransport at MCSs. PI4P drives lipid countertransport mediated by ORP5/8 at ER–PM MCSs (A) and by OSBP at ER–Golgi MCSs (B). (A) PI4K3α complex including EFR5A-B, TTC7A/B, and FAM126A/B synthesizes and concentrates PI4P at the PM (step 1). ORP5/8, both of which are anchored to the ER, form MCSs via interaction with PI4P and PI(4,5)P₂ by PH domain, and transport PI4P (driver-ligand) from the PM to the ER (step 2). Sac1 dephosphorylates PI4P to PI, which keeps the concentration of PI4P low at the ER (step 3). ORP5/8 transport PS (cargo-ligand) from the ER to the PM. (B) PI4K3β generates PI4P upon recruitment to the Golgi by regulatory proteins including Arf1 (step 1). Oxysterol-binding protein (OSBP) is recruited to the ER–Golgi MCSs via PH domain that interacts with PI4P and ACBD3 and/or Arf1 on the Golgi membranes and FFAT-motif that binds vesicle-associated membrane protein (VAMP)-associated protein A/B (VAPA/B). Then, OSBP mediates transport of PI4P (driver-ligand) from the Golgi to the ER (step 2). Sac1 hydrolyzes PI4P to PI (step 3). OSBP transports cholesterol (cargo-ligand) to Golgi (step 4). Synthesis and hydrolysis of PI4P by PI4Ks and Sac1 establishes a concentration gradient of this lipid between the ER and the PM/Golgi, which determines the flow of driver-ligand PI4P to the ER and counterflow of cargo-ligands from the ER.

LIPID TRANSPORT BY ORPs AT MEMBRANE CONTACT SITES

The ER, the site of the synthesis of most of lipids, is now known to make MCSs with most of the organelles or the PM where ORPs mediate transport or countertransport of lipids. Accumulating evidence demonstrates that ORP family proteins are widely localized at distinct MCSs and operate their own lipid transport/countertransport function (Figure 4 and Table 1). Furthermore, the tight regulation of such ORP function by phosphoinositides has also become evident. This section provides an overview of the role of ORPs in lipid transport or exchange at MCSs and their contributions to cellular biological processes. How phosphoinositides, such as PI4P, regulate ORP function will also be discussed.

Endoplasmic Reticulum–Plasma Membrane Membrane Contact Sites

ORP5/8

ORP5 and ORP8, which belong to group IV of the ORP family, have similar characteristics of domain structures (Figure 2). Both proteins have a PH domain, a coiled-coil domain, a linker region,
An ORP, and a membrane-spanning domain. Unlike other ORPs, ORP5 and ORP8 anchor to the ER via a membrane-spanning domain located at the C-terminus. The PH domain of ORP5 or ORP8 recognizes PI4P and/or PI(4,5)P2 in the PM with different preferences, thereby making an MCS between the ER and the PM (Chung et al., 2015b; Ghai et al., 2017; Sohn et al., 2018). It has been demonstrated that the ORD of ORP5/8 specifically harbors PI4P or PS and transfers them between liposomes in vitro. Intriguingly, the transfer of PS from donor to acceptor liposomes was strongly enhanced if another lipid ligand PI4P was present in the acceptor side, and the opposite combination also showed the same tendency, indicating an exchange activity of the ORP8 ORD (Chung et al., 2015b). In addition to PI4P and PS, the ORP5 ORD was shown to transport dehydroergosterol (DHE) in vitro, and this DHE transport was partially inhibited in the presence of PI4P in the donor liposomes (Du et al., 2011) (see the section “Endoplasmic Reticulum–Endosome/Lysosome/Autophagosome/Phagosome Membrane Contact Cites” for more details). In the cellular context, ORP5/8 exchanges PS with PI4P between the ER and the PM. Functional ablation of PI4K3a (the PI4P supplier at the PM) or Sac1 (the PI4P remover at the ER) disrupted the countertransport of those lipids, confirming that ORP5/8-mediated lipid countertransport is tightly coupled to the PI4P metabolic flow between the PM and the ER (Chung et al., 2015b) (Figure 3). This ORP5/8-mediated PI4P-driven lipid countertransport enables PS supply from the ER to the PM against its concentration gradient. Similarly, PI4P-driven PS transport at ER–PM MCSs has also been demonstrated in yeast (Moser von Filseck et al., 2015).

Several studies showed the regulation of PM PI(4,5)P2 by ORP5 and ORP8. Results from Sohn et al. (2018) support the role of ORP5/8 in exchanging PS with PI4P at ER–PM MCSs. In this study, BRET imaging quantitative assay was used to show that ORP5/8 controls PI(4,5)P2 levels by tuning the amount of its precursor PI4P, and this is basically controlled by their localization to the MCSs via the PH domain. The ORP5 PH domain requires both PI4P and PI(4,5)P2 for localization, although PI4P is still required even when PI(4,5)P2 production is increased. In the situation where PI(4,5)P2 is highly produced at the PM, PI4P levels become low due to ORP8 localization at the MCSs, thereby limiting PI4P availability for PI(4,5)P2 conversion by PIPKs. They proposed that this is a rheostat mechanism for tightly controlling the PI(4,5)P2 levels in a narrow range.
PI4P metabolic cycle generates the PI4P concentration gradient where it is hydrolyzed by the PI4P phosphatase Sac1, and this is due to the binding property of their PH domains to PI(4,5)P$_2$, but not to PI4P. Furthermore, the driver-ligand of the ORP5/8 ORD was proposed to be PI(4,5)P$_2$. In an in vitro lipid transport assay, they showed that the ORP8 ORD efficiently transports PI(4,5)P$_2$, and its concentration gradient between two liposomes enhanced the PS exchange. Consistent with this idea, PM PI(4,5)P$_2$ levels increased by knockdown of ORP5/8. These authors proposed that ORP5 and ORP8 are PI(4,5)P$_2$/PS exchangers in a PI(4,5)P$_2$-driven mechanism. Their conclusion regarding the role of ORPS and ORP8 in controlling PI(4,5)P$_2$ levels at the PM agreed with that of the Balla group, but the underlying mechanism differed. Because of the efficient in vitro PI(4,5)P$_2$ transfer activity in addition to a strong dependency on PI(4,5)P$_2$ for PM localization, the localization and function of ORP5/8 appear to be PI4P-independent. In the PI4P-driven model (Figure 3), PI4P is transported from the PM to the ER where it is hydrolyzed by the PI4P phosphatase Sac1, and this PI4P metabolic cycle generates the PI4P concentration gradient that drives lipid countertransport by ORP5 and ORP8 (Chung et al., 2015b). However, in the case of the PI(4,5)P$_2$-driven model, how PI(4,5)P$_2$ is metabolically degraded at the ER to create the concentration gradient of this lipid is still unknown. The authors mentioned that INPP5E might be involved in this process, but there is no evidence showing that INPP5E localizes at the ER and hydrolyzes PI(4,5)P$_2$ there. Instead, INPP5K, an ER-localized 5-phosphatase reported to hydrolyze PI(4,5)P$_2$ and PI(3,4,5)P$_3$, is a candidate, although the site of action of INPP5K has been proposed to be not only the ER, but also other membranes, including the PM, nucleus, and autolysosomes (Gurung et al., 2003; Ijuin and Takenawa, 2003; Hung et al., 2009; Dong et al., 2018; Ramos et al., 2020; McGrath et al., 2021).

ORP5/8-mediated countertransport and its relationship with the PI4P–PI(4,5)P$_2$–PS metabolic axis was further reported. A recent yeast study (Nishimura et al., 2019) showed that an osh-mediated lipid exchange mechanism generates a local domain containing unsaturated PS and sterol that promotes the localization and activation of PIPK, leading to PI(4,5)P$_2$ production. This study further points to the functional relationship between PI4P/PS exchange and PI(4,5)P$_2$ regulation. Additionally, a relationship between PS metabolism and MCS formation was also reported (Sohn et al., 2016) in studies of PSS1 (Kuge et al., 1991) and PSS2 (Kuge et al., 1997), the two PS synthases whose genetic mutation leads to Lenz-Majewski syndrome (Lenz and Majewski, 1974). The ER-localized enzyme PSS1 or PSS2 catalyzes PS production using PC or phosphatidylethanolamine (PE), respectively, as a substrate.

### TABLE 1 | Oxysterol-binding protein-related proteins (ORPs) that mediate transport or countertransport of lipids at membrane contact sites (MCSs).

| ORPs | Lipid activity in vitro | Localization at ER MCS (lipids transferred or exchanged) | References |
|------|------------------------|----------------------------------------------------------|------------|
| OSBP | PI4P/DHE | ER-Golgi (PI4P/Sterol), ER-Endosome (PI4P), ER-LE/Ly (PI4P/Cholesterol) | Mesmin et al. (2013, 2017), Dong et al. (2016), Goto et al. (2016), Lim et al. (2019) |
| ORP1 | DHE | ER-LE/Ly (Cholesterol), ER-phagosome (PI4P) | Eden et al. (2016), Zhao and Ridgway (2017), Dong et al. (2019), Levin-Kongsberg et al. (2019) |
| ORP2 | PI(4,5)P$_2$/DHE | ER-LD | Weber-Boyvat et al. (2015a) |
| ORP3 | ? | ER-PM (PI4P) | Weber-Boyvat et al. (2015a), D’Souza et al. (2020), Gulyás et al. (2020) |
| ORP4 | Cholesterol | ER-Golgi | Wyles et al. (2007), Charman et al. (2014), Pietrangelo and Ridgway (2018) |
| ORP5 | PI4P/PS, PI(4,5)P$_2$/PS, DHE | ER-PM (PI4P/PS), ER-PM (PI(4,5)P$_2$/PS), ER-LD (PI4P/PS), ER-Mito | Chung et al. (2015a), Galmes et al. (2016), Ghai et al. (2017), Sohn et al. (2018) |
| ORP6 | ? | ER-PM (PI4P) | Mochizuki et al. (2018) |
| ORP7 | ? | ? | |
| ORP8 | PI4P/PS, PI(4,5)P$_2$/PS | ER-PM (PI4P/PS), ER-PM (PI(4,5)P$_2$/PS), ER-Mito | Chung et al. (2015a), Galmes et al. (2016), Ghai et al. (2017), Sohn et al. (2018) |
| ORP9 | Cholesterol | ER-Golgi | Ngo and Ridgway (2009), Venditti et al. (2019b) |
| ORP10 | ? | ER-Golgi (PS) | |
| ORP11 | ? | ? | |

---

*Lipids were transported or exchanged between liposomes in vitro. The exchanged lipids are separated by slash (/).*

*Lipids demonstrated to be transported or exchanged in intact cells are shown in parentheses. The exchanged lipids are separated by slash (/).*

*Lipids shown in bold font: transport or exchange of the indicated lipids has been demonstrated in loss-of-function or gain-of-function analysis in an acute manner (e.g., acute inhibition or manipulation of ORP proteins).*

*Lipids shown in regular font: transport or exchange of the indicated lipids has been suggested in loss-of-function or gain-of-function analysis in a chronic manner (e.g., chronic inhibition [knock-down or knock-out] or overexpression of ORP proteins).*

*Unknown.*
Nakatsu and Kawasaki

ORP-Mediated Lipid Transport/Countertransport at MCSs

FIGURE 5 | Regulation of PI4P and PI(4,5)P\textsubscript{2} at the PM by oxysterol-binding protein-related proteins 5 and 8. (A) At steady state, ORP5 localizes at the ER–PM MCSs via binding to PI4P and PI(4,5)P\textsubscript{2}. (B) When PI(4,5)P\textsubscript{2} is high at the PM, ORP8 is strongly recruited to the PM via preferential binding to PI(4,5)P\textsubscript{2} and mediates countertransport of PI4P and PS. This reduces PI4P levels at the PM and thus contributes indirectly to reducing PI(4,5)P\textsubscript{2} levels by limiting its precursor. ORP8-mediated countertransport of PS to the PM may facilitate the activation of PIPKs (Nishimura et al., 2019).

Their enzyme activity was shown to be inhibited by the end product PS, and the mutation responsible for this feedback inhibition, which caused Lenz–Majewski syndrome, leads to PS accumulation in the ER (Sousa et al., 2014). Inhibition of PI4K3α by the specific inhibitor A1 decreases the PM PI4P levels, and this results in the inhibition of PS synthesis by approximately 50%. This is likely a homeostatic regulation because PS synthesis needs to be slowed down in a situation where PI4P-driven PS transport is slow. In fact, expression of the PSS1 disease mutant, which reflects a disease condition where PS accumulated at the ER, led to a reduction of ORP8 membrane association as well as a decrease in PM PI4P levels (Sohn et al., 2016). Collectively, PI4P-driven lipid countertransport mediated by ORP5 and ORP8 is tightly coupled to homeostasis of lipids such as PI4P, PI(4,5)P\textsubscript{2}, and PS at the PM and the ER (Balla et al., 2019, 2020; Pemberton et al., 2020a; Santos et al., 2020) (Figure 5).

ORP3

ORP3 is categorized in group III, together with ORP6 and ORP7 (Figure 2). ORP3 contains a typical cytosolic ORP family domain architecture, such as a PH domain, FFAT-motif, and ORD. ORP3 is basically cytosolic at steady state, but translocates to the ER–PM MCSs upon PKC activation and Ca\textsuperscript{2+} influx (Weber-Boyat et al., 2015a; Gulyás et al., 2020). ORP3 associates with the ER via FFAT motif-mediated binding to VAP, and it appears to be phosphorylation dependent (Lehto et al., 2005; Weber-Boyat et al., 2015a). The PM association of ORP3 is mediated by its PH domain that recognizes PI4P and PI(4,5)P\textsubscript{2} (Gulyás et al., 2020). Such phosphorylation-dependent binding of ORP3 to VAP and the PM might imply that phosphorylation may induce a conformational change that unmasks the PH domain and FFAT-motif. Colocalization of ORP3 with ORP6 or ORP8 at the ER–PM MCSs has been reported (Weber-Boyat et al., 2015a; Mochizuki et al., 2018). ORP3-mediated ER–PM MCS formation has been linked to cellular processes such as Ca\textsuperscript{2+} regulation, adhesion, and migration (Machaca, 2020). A recent study (D’Souza et al., 2020) provided a mechanistic insight into how ORP3 controls focal adhesion dynamics. Those studies indicate the following scenario. Store-operated Ca\textsuperscript{2+} entry (SOCE) by STIM1-Orai1 axis activates PKC and then induces the ORP3 translocation to the ER–PM MCSs where STIM1 and Orai1 also localize. This ORP3 translocation occurs around the focal adhesion where ORP3 recruits the
guanin exchange factor IQSec1 that activates Arf5, thereby promoting the disassembly of focal adhesion at the rear front of the cell. How ORP3-mediated lipid transport/countertransport is involved in those processes, however, is still unclear. This is because the ligand(s) of the ORD have not been firmly identified. However, an imaging study showing a strong reduction of PI4P, but not of PI(4,5)P₂, PI(3,4,5)P₃, or PS, at the PM after acute recruitment of ORP3 to the ER–PM MCS, suggests PI4P as a ligand of the ORD (Gulyás et al., 2020). Other cargo-ligand(s) could be PC or cholesterol (D’Souza et al., 2020; Gulyás et al., 2020). However, whether ORP3 is indeed an exchanger of those candidate ligands has not been clearly demonstrated and, thus, needs further investigation.

**ORP6**

ORP6 is another member in group III (Figure 2). Like ORP3, ORP6 also shows a typical domain architecture such as N-terminal PH domain, FFAT-motif, and ORD. Mochizuki et al. (2018) demonstrated that ORP6 colocalized with ORP3 or extended synaptotagmins (E-Syts), but not with ORP5, at the ER–PM MCSs in neuronal cells such as Neuro2A or primary cerebellar granule cells. The ORP6 PH domain binds PI4P, PI(4,5)P₂, and phosphatidic acid (PA) in a membrane lipid strip assay. ORP6 knockdown led to an increase in PM PI4P detected by the OSBP PH domain probe, suggesting that ORP6 contributes to the PI4P turnover at the PM. However, whether ORP6 mediates transport or countertransport of lipids is still unclear, as well as its contribution to cell physiology.

**Endoplasmic Reticulum–Golgi Membrane Contact Sites**

**OSBP**

OSBP is the founding member of the ORP family (Raychaudhuri and Prinz, 2010) (Figure 2). The domain architecture is PH domain, FFAT-motif, and ORD, the typical ORP family domain structure. OSBP represents both a cytosolic pool and membrane-bound status. Initially, OSBP was shown to associate with the Golgi including the TGN, but also with endosomes or lysosomes in later studies. The membrane targeting of OSBP is mediated by PH domain as is the case for other ORPs. According to an in vitro liposome-binding assay, the OSBP PH binds PI4P and PI(4,5)P₂ (Rameh et al., 1997; Levine and Munro, 1998). However, a study using yeast as a model (Levine and Munro, 2002) showed the OSBP PH domain localizes in the Golgi, and this Golgi localization was abolished upon deletion of the PI4-kinase pik1 (the yeast ortholog of mammalian PI4Kβ3 that synthesizes PI4P at the Golgi). The deletion of the PI4-kinase mss4 [the yeast ortholog of mammalian PIPKs that generates PI(4,5)P₂], however, did not abolish the Golgi localization of the OSBP PH domain, indicating that PI4P is the key to Golgi localization in situ. Furthermore, the OSBP PH domain also interacted with the GTP-bound form of Arf1, the small GTPase that controls membrane association of Golgi proteins (Levine and Munro, 2002). Arf1 also controls recruitment to the Golgi of PI4Kβ3, the PI4K responsible for the synthesis of a pool of PI4P at this organelle (Godi et al., 1999). PI4Kβ3, another PI4K that synthesizes PI4P at endosomes and the TGN (Wang et al., 2003), is also shown to provide a pool of PI4P at the TGN for OSBP recruitment (Mesmin et al., 2017). Thus, the OSBP PH domain recognizes both PI4P and GTP-Arf1. This coincident detection mechanism ensures the targeting of OSBP to the Golgi, and thus, OSBP localizes at ER–Golgi MCSs with the FFAT motif captured by VAP at the ER.

The OSBP ORD has been demonstrated to exchange PI4P and cholesterol between the ER and Golgi (Mesmin et al., 2013). This idea, basically, came from a study by de Saint-Jean et al. (2011) using osf4 as a model. Extraction of fluorescent ergosterol DHE by Osh4p, which was previously shown to bind sterol in its ORD, was inhibited by PI4P, but not by many other lipids tested. This was due to the surprising ability of the osh4 ORD to solubilize PI4P by itself. In fact, crystal structural analysis clearly revealed that osf4 specifically harbors PI4P or cholesterol in its ORD. The acyl chain of PI4P is inserted deep inside the pocket, and the head group of PI4P is also shown to provide a pool of PI4P at the TGN. However, another study demonstrated no major impact on PI4P levels at the TGN. In fact, the OSBP-mediated PI4P transport between liposomes (de Saint-Jean et al., 2011).

The study above led to the discovery of OSBP function at ER–Golgi MCSs. Mesmin et al. (2013) demonstrated that OSBP exchanges cholesterol and PI4P at ER–Golgi MCSs. Mechanistically, OSBP extracts PI4P from the Golgi membranes and transfers it to the ER, and this PI4P flow along its gradient ensures the back transfer of cholesterol against the gradient by OSBP (Figure 3). Functionally, OSBP has been estimated to mediate one-third to two-thirds of cholesterol transport by consuming approximately half of the total cellular PI4P, according to an acute pharmacological inhibition study (Mesmin et al., 2017) using the chemical OSW-1 (Burgett et al., 2011). Such inhibition of OSBP led to a roughly fourfold increase in PI4P levels at the TGN and a roughly twofold increase in whole cells. A recent study using a different inhibitor also reported a similar effect (Péresse et al., 2020). These data suggest the physiological contribution of OSBP in the regulation of PI4P and cholesterol at the TGN. However, another study demonstrated no major impact on PI4P levels at the TGN by OSBP knockdown or addition of 25-hydroxycholesterol (Goto et al., 2016). Chronic inhibition by knockdown (in contrast to acute inhibition) as well as a cell type difference might be the reasons for the apparently different results. Regarding the 25-hydroxycholesterol, no inhibitory (but even a slight stimulatory) effect on the OSBP-mediated PI4P transport between liposomes has been demonstrated (Mesmin et al., 2017). This could be a possible explanation for the very minor effect of this lipid on the PI4P levels in the TGN. Collectively, OSBP regulates PI4P levels at the TGN.

**ORP4**

ORP4 belongs to group I, together with OSBP (Figure 2). ORP4 has a PH domain, FFAT motif, and ORD, and there is a short isoform containing only an ORD. ORP4 has been detected in the brain, kidneys, heart, skeletal muscles, and spleen by Northern blot analysis of human tissues (Wang et al., 2002), as well as in the brain and testis by Western blot analysis of
mouse tissues (Udagawa et al., 2014). The PH domain bound to PI4P in a membrane lipid strip assay, as well as in a liposome-binding assay (Charman et al., 2014). In CHO cells, the PH domain of ORP4 weakly associated with the Golgi. The purified protein containing the ORP4 ORD binds 25-hydroxycholesterol to extract and transfer cholesterol between liposomes (Charman et al., 2014). ORP4 was shown to interact with OSBP and localizes to the Golgi in an OSBP-dependent manner, suggesting that ORP4 functions at the ER-Golgi MCSs with OSBP (Wyles et al., 2007; Pietrangelo and Ridgway, 2018). However, whether ORP4 mediates transport or countertransport of PI4P and/or cholesterol is unknown. ORP4 has been implicated in several cancers, including leukemia, as a signaling regulator; however, its role as an LTP in MCSs is unclear (Fournier et al., 1999; Silva et al., 2001; Henriques Silva et al., 2003; Zhong et al., 2016).

**ORP9**

ORP9 is the sole member in group V (Figure 2). The domain structure of the full-length long form is a typical one containing a PH domain, FFAT motif, and ORD. The short isoform lacking the PH domain has also been reported. The ORP9 PH domain binds mono-phosphorylated phosphoinositides according to a lipid membrane overlay assay and cosediments with liposomes containing PI4P (Ngo and Ridgway, 2009). Purified full-length ORP9 proteins extract cholesterol and PI4P, but not oxysterol or PS, from liposomes in vitro and transfer cholesterol between liposomes (Ngo and Ridgway, 2009; Liu and Ridgway, 2014). This cholesterol transfer activity is enhanced if the donor liposomes also contain PI4P, and this enhancement is dependent on its PH domain, suggesting that such enhancement is due to the efficient targeting of purified ORP9 proteins to the donor liposomes by PH domain (Ngo and Ridgway, 2009). Whether ORP9 exchanges PI4P and cholesterol is still unknown. ORP9 localizes partially at the TGN and does not colocalize with PI4K3β. ORP9 knockdown in HeLa cells did not alter the PI4P levels in the TGN, as assessed by immunofluorescence staining with anti-PI4P antibody (Liu and Ridgway, 2014). A recent study demonstrated a role of ORP9 in the integrity of ER–TGN MCSs as its depletion in addition to simultaneous depletion of OSBP affects the formation of ER–TGN MCSs assessed by FLIM (fluorescence lifetime imaging) (Venditti et al., 2019b).

**ORP10**

ORP10 is a member of group VI, and it has a PH domain and an ORD, but lacks a FFAT motif (Figure 2). ORP10 is reported to localize at the Golgi via its PH domain. The ORD of ORP10 has been shown to extract PS from liposomes (Maeda et al., 2013). Venditti et al. (2019b) demonstrated that ORP10 localized at the MCSs between the ER and TGN. ORP10 depletion in HeLa cells affects the integrity of ER–TGN MCSs and leads to reduced PS levels in the Golgi, suggesting its role as a PS transporter. The residues involved in binding to PI4P and PS in the ORP5/8 ORD are well conserved in ORP10, and mutations in these residues were shown to abolish the ability to rescue the integrity of the MCSs in ORP10-deficient cells. These results suggest that ORP10 might be a lipid exchanger. However, a lipid exchange function of ORP10 has not been demonstrated.

**Endoplasmic Reticulum–Endosome/Lysosome/Autophagosome/Phagosome Membrane Contact Sites**

**OSBP**

OSBP has been reported to localize to MCSs other than the Golgi. Dong et al. (2016) demonstrated the function of OSBP at ER–endosome MCSs. OSBP knockdown as well as VAPA/VAPB deletion leads to endosomal PI4P accumulation and then actin reorganization such as the loss of stress fibers and WASH-dependent actin comet formation. OSBP-mediated transport of PI4P from endosomes to the ER contributes to the negative regulation of PI4P at endosomes. Sobajima et al. (2018) showed the function of OSBP at the MCSs between endosomes and the TGN, but not the ER. OSBP interacts with RELCH, a novel Rab11-GTP effector, and tethers recycling endosomes to the TGN by the OSBP–RELCH-Rab11 complex. This complex mediates the transfer of cholesterol from recycling endosomes to the TGN (Sobajima et al., 2018). Another study (Lim et al., 2019) also indicates the role of OSBP-mediated cholesterol transport at ER–lysosome MCSs. OSBP was found to supply cholesterol to lysosomes via ER–lysosome MCSs. This pool of cholesterol in the limiting membrane of lysosomes triggers the activation of mTORC1, the master regulator of growth, via Rag GTPases as well as the amino acid permease SLC38A9 (Castellano et al., 2017). In fact, OSBP inhibition by the chemical inhibitor OSW1 or shRNA-mediated knockdown reduced cholesterol accumulation on the lysosomal-limiting membranes in cells lacking Niemann Pick C type 1 (NPC1), thereby suppressing the hyperactivation of mTORC1 (Lim et al., 2019). The studies described above all indicate an important role of OSBP as a transporter, but not as a bona fide exchanger, of lipid ligands at several MCSs. Despite the fact that OSBP is an exchanger of PI4P and cholesterol at the ER and Golgi, whether and how such exchange activity of OSBP support those functions at the MCSs other than Golgi is currently unclear.

**ORP5**

ORP5 has been suggested to functionally contribute to the cholesterol transport from late endosomes/lysosomes to the ER (Du et al., 2011). Purified ORP5 ORD mediates transfer of DHE between liposomes, and this activity is partially inhibited by PI4P, but not by PI3P, PI5P, or PI(4,5)P2, suggesting a possibility of ORP5 as a cholesterol transporter. Transiently expressed full-length ORP5 or its ORD was co-immunoprecipitated with either OSW1 or shRNA-mediated knockdown reduced cholesterol accumulation on the lysosomal-limiting membranes in cells lacking Niemann Pick C type 1 (NPC1), thereby suppressing the hyperactivation of mTORC1 (Lim et al., 2019). The studies described above all indicate an important role of OSBP as a transporter, but not as a bona fide exchanger, of lipid ligands at several MCSs. Despite the fact that OSBP is an exchanger of PI4P and cholesterol at the ER and Golgi, whether and how such exchange activity of OSBP support those functions at the MCSs other than Golgi is currently unclear.
transporter *via* MCSs between the ER and lysosomes, although such MCS formation has not been demonstrated to date.

**ORP1**

ORP1, which belongs to group II together with ORP2, exists in long (L) and short (S) forms (*Figure 2*). ORP1L contains ankyrin repeats in addition to other typical domains for ORPs such as a PH domain, FFAT-motif, and ORD. ORP1S encodes only an ORD but lacks other domains. Purified PH domain of ORP1L binds weakly PI(3,4)P$_2$, PI(3,5)P$_2$, and PI(3,4,5)P$_3$ in liposome-binding assay (Johansson et al., 2005). ORP1L binds Rab7 *via* ankyrin repeats (Johansson et al., 2005) as well as VAP *via* FFAT motif and, hence, localizes at the MCSs between the ER and late endosomes/lysosomes or autophagosomes. The ORP1 ORD binds oxysterol, cholesterol, and PI4P (Vihervaara et al., 2011; Zhao and Ridgway, 2017; Zhao et al., 2020). Dong et al. (2019) reported that the ORD binds all of the phosphoinositides with a similar extent compared with DHE but does not bind PS. Lipid transfer activity of the ORP1 ORD has also been demonstrated (see below). However, its exchange activity has not been reported to date.

**Cholesterol Transport by ORP1**

Dong et al. (2019) reported that the purified ORP1 ORD protein transports cholesterol or DHE between liposomes *in vitro*, and its transfer activity is enhanced in the presence of PI(3,4)P$_2$ or PI(4,5)P$_2$ in the acceptor liposomes. However, the backward transfer of those phosphoinositides was not detected. Another study by Zhao and Ridgway (2017) reported that extraction of cholesterol from liposomes by purified full-length ORP1 protein was inhibited by the addition of PI4P, but not other phosphoinositides including PI(4,5)P$_2$, to the liposomes. Consistent with this result, ORP1 protein extracts isotope-labeled PI4P from liposomes. Thus, these *in vitro* studies suggest that the ORP1 ORD is able to transport cholesterol, but may not transport phosphoinositides. In the cellular extent, ORP1L has been shown to mediate transport of cholesterol or PI4P (see below) at late endosome–ER MCSs. In the absence of exogenous low-density lipoprotein (LDL), which can be a source of late endosomal cholesterol *via* endocytosis, ORP1L mediates cholesterol transport to late endosomes from the ER, the site of its synthesis (Eden et al., 2016). This cholesterol transport can be driven by countertransport of PI4P in theory, but such countertransport has not yet been reported. Other studies also support the cholesterol transport, but its direction is opposite. Zhao and Ridgway (2017) demonstrated that accumulation of cholesterol in late endosomes in ORP1L-deficient HeLa cells was rescued by expression of wild-type, but not of mutants lacking the ORD or FFAT motif, suggesting that ORP1L mediates transfer of LDL-derived cholesterol from late endosomes to the ER along its concentration gradient. This ORP1L-mediated cholesterol transfer requires NPC1, which delivers LDL-cholesterol to the limiting membranes of late endosomes. Surprisingly, the mutant ORP1L, which is unable to bind PI4P due to disruption of the conserved PI4P-binding histidine residues in its ORD, did not rescue the cholesterol accumulation phenotype. This implies possible involvement of PI4P in the cholesterol transport, although it is difficult to reconcile at this moment how PI4P contributes to this cholesterol regulation. Dong et al. (2019) also supported the idea that ORP1L mediates cholesterol transport from late endosomes to the ER. Consistent with their *in vitro* data showing that the cholesterol transport activity of ORP1L is enhanced by PI(3,4)P$_2$ or PI(4,5)P$_2$, inhibition of PI(3,4)P$_2$ synthesis by PI3KC2β on late endosomes (Marat et al., 2017) phenocopied the cholesterol transport defect. Collectively, ORP1L functions as a cholesterol transporter with or without the help of phosphoinositides, but its transport might be bi-directional between the ER and late endosomes/lysosomes depending on the cholesterol concentration.

**Phosphatidylinositol 4-Phosphate Transport by ORP1**

PI4P transport by ORP1L has been demonstrated at the MCSs between the ER and phagosomes. Phagosomes are endocytic organelles that engulf extracellular materials including microorganisms and apoptotic cells, and eventually fuse with lysosomes that degrade them. It has recently been demonstrated that ORP1L localizes at the MCSs between the ER and phagolysosomes, the mature phagosomes, where it mediates transport of PI4P from phagolysosomes to the ER (Levin-Konigsberg et al., 2019). The disappearance of PI4P from phagolysosomes, evaluated by live imaging, was delayed in ORP1L KO RAW 264.7 cells, and this delay was rescued by reexpression of wild-type ORP1L but not of the PI4P-binding mutant or the FFAT motif mutant. This ORP1L-mediated PI4P transport contributes to the segregation and concentration of this lipid into a domain that recruits the SKIP–ARL8B–kinesin complex (*via* PI4P binding of SKIP PH domain) leading to tubulation and fission of PI4P-positive membranes of phagolysosomes. Given that membrane-associated free cholesterol increases with phagosome maturation (Rai et al., 2016), such ORP1L-mediated PI4P transport to the ER might be coupled to back-transfer of cholesterol to the phagolysosomes. This interesting possibility needs further investigation.

**Cholesterol Sensing by ORP1**

ORP1L has been shown to control dynamics of late endosomes/lysosomes as a cholesterol sensor. Rab7 is a small GTPase that localizes at those organelles and controls a variety of their functions including subcellular positioning (Zerial and McBride, 2001; Cabukusta and Neefjes, 2018). ORP1L localizes at late endosomes/lysosomes *via* its PH domain and binding to Rab7 as an effector. Rab7 also recruits another effector RILP (Cantalupo et al., 2001; Jordens et al., 2001), which is the adaptor protein connecting Rab7 to the dynein–dynactin motor complex by binding to the light intermediate chain of dynein (Schroeder et al., 2014) and p150Glu subunit of dynactin (Johansson et al., 2007). Interaction of Rab7–ORP1L–RILP to the dynein–dynactin motor complex, thus, determines the positioning of late endosomes/lysosomes, but this interaction is controlled by ORP1L-mediated cholesterol sensing. When the cholesterol levels are high in the limiting membrane of late endosomes, ORP1L accommodates cholesterol, leading
vesicles such as exosomes or microvesicles are taken up via membrane is continuous with the ER membrane. Extracellular late endosomes and the nuclear envelope (NE), whose outer ORP3 has been reported to localize at the MCSs between ORP3 is still unclear. 

to such positioning control of late endosomes/lysosomes transport or countertransport activity of ORP1L contributes reported for autophagosomes (Wijdeven et al., 2016). How lipid dynein–dynactin motor complex. Similar regulation was also promoting or inhibiting the binding capacity of RILP to the connecting or disconnecting those organelles to microtubules via or inhibiting the binding capacity of RILP to the dynein–dynactin motor complex. Similar regulation was also reported for autophagosomes (Wijdeven et al., 2016). How lipid transport or countertransport activity of ORP1L contributes to such positioning control of late endosomes/lysosomes is still unclear.

ORP3

ORP3 has been reported to localize at the MCSs between late endosomes and the nuclear envelope (NE), whose outer membrane is continuous with the ER membrane. Extracellular vesicles such as exosomes or microvesicles are taken up via endocytosis by recipient cells, and their contents (e.g., nucleic acids, proteins, or lipids) are then delivered into the cytosol or other compartments (Raposo and Stoorvogel, 2013; van Niel et al., 2018). However, the underlying mechanism of the delivery of EV components is not completely understood (Mathieu et al., 2019). Rappa et al. (2017) demonstrated that EV components are transported along the endocytic pathway to a subset of Rab7-positive late endosomes, which are located in the nucleoplasmic reticulum in a deep nuclear envelope invagination. A subsequent study by the same group showed that such late endosomes contact the outer nuclear membranes in nuclear envelope invagination through tethering by ORP3 and VAPA. Functional ablation of ORP3 or VAPA (but not VAPB) leads to malfunction of NE-late endosome MCSs in the nucleoplasmic reticulum and inhibits the transport of EV components such as CD9 or nucleic acids into the nucleoplasm, suggesting that ORP3-mediated MCSs contribute to delivering EV contents to the nucleus (Santos et al., 2018). Given that the nucleoplasmic reticulum is involved in $Ca^{2+}$ regulation (Echevarría et al., 2003), the localization and function of ORP3 at the NE-late endosome MCSs may also be coupled to $Ca^{2+}$ regulation, as shown at the ER–PM MCSs (Weber-Boyvat et al., 2015a; D’Souza et al., 2020; Gulyás et al., 2020). However, the targeting mechanism and lipid transport function of ORP3 in moving EV components into the nucleus remains unknown.

Endoplasmic Reticulum–Lipid Droplet Membrane Contact Sites

ORP2

ORP2 is a member of group II (Figure 2). It has an FFAT motif and ORD, but lacks a PH domain. The ORP2 ORD binds oxysterol, cholesterol, and phosphoinositides such as PI4P, PI(4,5)P2, PI(3,5)P2, and PI(3,4,5)P3 in vitro (Xu et al., 2001; Hynynen et al., 2005, 2009; Suchanek et al., 2007). ORP2 has been suggested to function at the lipid droplets (LDs). ORP2 localizes to the surface of LDs or MCSs between the ER and LDs. Loss of function studies suggest that ORP2 may control triacylglycerol metabolism as well as lipolysis in LDs (Weber-Boyvat et al., 2015b). How ORP2 targets the LDs, however, is unclear. A recent study showed the association of ORP2 with the COP1 machinery, which has been demonstrated to transport proteins to the LDs (Soni et al., 2009; Wilfling et al., 2014). ORP2 might utilize COP1 to target LDs. Whether and how ORP2 exerts its function as a lipid transporter/exchanger is also unknown.

ORP5

ORP5, but not ORP8, is shown to localize and function at the ER–LD MCSs. ORP5 localizes LDs upon oleate loading, and its localization is mediated by ORD. Mutations in the lipid binding residues of ORP5 ORD abolished its localization, suggesting that PI4P/PS transport activity is required for the LD targeting. ORP5 knockdown increased the size of LDs, although no morphological change was reported in the previous study by the same group (Du et al., 2011). ORP5 knockdown also leads to an increase in PI4P and a decrease in PS on the LD surface. PI4K2α, but not other PI4Ks, was responsible for the generation of a pool of PI4P on LDs in ORP5 KD cells. ORP5 has been proposed to control the function of LDs via PI4P/PS countertransport, which is similar to that at the ER–PM MCSs but is supported by a different kinase, PI4K2α. However, direct evidence of the PI4P/PS exchange at the ER–LD MCSs in situ seems to be rather weak. It is quite interesting to find that ORP5 has a pleiotropic function as a PI4P/PS exchanger at multiple MCSs. However, many questions remain elusive. What is the physiological significance of PS transport to LDs? How does PI4K2α, which is a palmitoylated endosomal protein (Balla et al., 2002; Balla and Balla, 2006), contribute to the synthesis of the pool of PI4P on LDs? How is the localization (and hence the MCS formation) of ORP5, which does not require its PH domain, precisely controlled? Answering those questions may advance our understanding of ORP5 functions as well as novel aspects of LD biology.

Endoplasmic Reticulum–Mitochondria Membrane Contact Sites

ORP5/8

ORP5 as well as ORP8 seem to have pleiotropic functions at multiple MCSs. ORP5 and ORP8 have been shown to localize at the ER–mitochondria MCSs (Galmes et al., 2016). Immunofluorescence staining and immunogold electron microscopy revealed the localization of both ORP5 and ORP8 at the MCSs between the ER and mitochondria in HeLa cells. Fractionation experiments showing the enrichment of
ORP5 and ORP8 in mitochondria—associated ER membranes (MAMs) also support their localization at the ER–mitochondria MCSs. Localization of ORP5/8 to the ER–mitochondria MCSs does not require their PH domain but, instead, requires their novel binding partner, protein tyrosine phosphatase-interacting protein-51 (PTPIP51). PTPIP51 is the mitochondrial outer membrane protein that localized at the ER–mitochondria MCSs via interaction with VAPB and is involved in Ca^{2+} regulation at the mitochondria (Stoica et al., 2014). The ORD of ORP5 and ORP8 interacts with PTPIP51, and this interaction is required for their localization to the MCSs. Interestingly, though, the ORD mutant that abolishes PS binding cannot localize at the MCSs due to loss of binding to PTPIP51. Given that PS is transported to mitochondria to be converted to PE, ORP5/8 may contribute to PS transport to this organelle for PE synthesis. However, whether ORP5 and ORP8 mediate countertransport of PI4P and PS has not been confirmed. Nevertheless, the presence of PI, the precursor of PI4P, in the mitochondrial membrane was reported (Pemberton et al., 2020b; Zewe et al., 2020). Furthermore, the presence of PI4P-containing vesicles at the ER–mitochondria MCSs was also recently reported, although this pool of PI4P was provided via vesicular transport from the TGN after synthesis by PI4K3β (Nagashima et al., 2020). These observations suggest an interesting possibility of a direct involvement of PI4P in PS transport to mitochondria mediated by ORP5 and ORP8. These important aspects of whether and how ORP5/8 and PI4P contribute to such a process need further investigations.

**DISCUSSION**

In eukaryotes, more than 1,000 species of lipid molecules are coordinated to support fundamental cellular activities. In order to be fully functional, each lipid must be correctly positioned at the right place at the right time. Non-vesicular lipid transport by LTPs, including ORPs, controls such spatiotemporal positioning of lipids in cells (Holthuis and Menon, 2014). LTPs transfer their own set of lipid ligands between cellular membranes. ORPs, originally identified as oxysterol-binding proteins, have now been characterized as sensors or transporters of multiple lipids at MCSs. Biochemical studies as well as structural analysis have demonstrated that ORPs have a multiple-ligand repertoire, including not only cholesterol but also phospholipids such as phosphoinositides, PS, and/or PC. Moreover, ORPs widely localize at multiple MCSs in cells to mediate transport of their own different lipid ligands, suggesting a functional diversity of ORPs to handle numerous cellular processes.

A unique functional property of ORPs is their lipid countertransport function at MCSs. Several, but not all, ORPs have been shown to exchange two different lipids: PI4P as a common driver-ligand and another lipid as a cargo-ligand. In the case of ORP5/8, they form ER–PM MCSs where PI4P and PI(4,5)P2 are enriched, and transport PI4P along its concentration gradient to the ER where PI4P is dephosphorylated by the PI4P phosphatase Sac1 (Chung et al., 2015b; Ghai et al., 2017; Sohn et al., 2018). This PM-to-ER flow of PI4P ensures the ER-to-PM counter-directional transport of the cargo-ligand PS against its concentration gradient. PI4K3α and Sac1 generate a concentration gradient of PI4P, the driver of this lipid countertransport, while ORP5/8 are the operators of lipid exchange at MCSs.

Although a better understanding of the role of ORPs as lipid transporters/exchangers at MCSs is emerging, many questions arise and remain unanswered. First, we do not know whether all ORPs act as lipid exchangers. As described above, some ORPs function as lipid exchangers in a PI4P-dependent manner. Considering that PI4P is distributed at cellular membranes such as the PM, Golgi, endosomes, and lysosomes (Hammond et al., 2014) (Figure 1), PI4P-driven lipid countertransport would be widely operated by ORPs at MCSs between those PI4P-containing membranes and the ER. In fact, structural analysis has suggested that PI4P might be the common ligand of ORPs (Tong et al., 2013; Antonny et al., 2018). Nevertheless, some ORPs have shown no lipid exchange activity and behave as transporters or sensors of lipids, suggesting that all ORPs may not necessarily be an exchanger. Second, the dynamic nature of ORPs at MCSs need to be understood. From a metabolic standpoint, cellular lipids must be under tight control in their quantity, quality, and distribution in response to changes in cellular status. How do ORPs dynamically change their localization at MCSs? How is their lipid transport/countertransport activity regulated? Such questions, especially in the context of cellular lipid homeostasis, would be important issues. Third, technical and methodological advancement will greatly help our understanding of the role of ORPs. Detection or analysis of lipids at organellar levels by imaging techniques will continue to provide useful information. Manipulation of lipids as well as ORP proteins in cells by chemical biology or some other genetic techniques will also give us novel insights. Last but not the least, the physiological significance of ORP-mediated lipid transport/countertransport in the regulation of lipid metabolism as well as some other processes must be further investigated. In particular, how such lipid countertransport at MCSs directly regulates specific cellular functions other than lipid metabolism remains elusive. In addition, the physiological role of ORPs at tissue or animal levels is largely unknown. The physiological importance of the intracellular lipid transport/countertransport by LTPs is underscored by human diseases caused by defects in such regulation. As the connection between malfunctions of intracellular lipid transport and various human diseases becomes progressively evident, a comprehensive understanding of the role of intracellular lipid transport is increasingly important.

**AUTHOR CONTRIBUTIONS**

FN and AK wrote the manuscript and prepared the figures. Both authors contributed to the article and approved the submitted version.
Henriques Silva, N., Vasconcellos Fournier, M., Pimenta, G., Pulcheri, W. A., Ijuin, T., and Takenawa, T. (2003). SKIP negatively regulates insulin-induced GLUT4 translocation and membrane ruffle formation. *Mol. Cell Biol.* 23, 1209–1220. doi: 10.1128/mcb.23.4.1209-1220.2003

Im, Y. J., Raychaudhuri, S., Prinz, W. A., and Hurley, J. H. (2005). Structural mechanism for sterol sensing and transport by OSBP-related proteins. *Nature* 437, 134–158. doi: 10.1038/nature03923

Johansson, M., Lehto, M., Tanhuuapää, K., Cover, T. L., and Ollkonen, V. M. (2005). The oxyester-binding protein homologue ORP1L interacts with Rab7 and alters functional properties of late endocytic compartments. *Mol. Biol. Cell* 16, 5480–5492. doi: 10.1091/mbc.e05-03-0189

Johansson, M., Rocha, N., Zwart, W., Jordens, I., Janssen, L., Kuijl, C., et al. (2007). Activation of endosomal dynein motors by stepwise assembly of Rab7-RILP-p150Glue, ORP1L, and the receptor betallillin. *J. Cell Biol.* 176, 459–471. doi: 10.1083/jcb.200606077

Jordens, I., Fernandez-Borja, M., Marsman, M., Dusseljee, S., Janssen, L., Calafat, J., et al. (2001). The Rab7 effector protein RILP controls lysosomal transport by inducing the recruitment of dynein-dynactin motors. *Curr. Biol.* 11, 1680–1685. doi: 10.1016/S0960-9822(01)00531-0

Judith, D., Jefferies, H. B. I., Boehing, S., Frith, D., Snijders, A. P., and Tovee, S. A. (2019). ATG9A shapes the forming autophagosome through Arfaptin 2 and phosphatidylinositol 4-kinase IIβ. *J. Cell Biol.* 218, 1634–1652. doi: 10.1083/jcb.201901115

Kuge, O., Nishijima, M., and Akamatsu, Y. (1991). A Chinese hamster cDNA encoding a protein essential for phosphatidylserine synthase 1 activity. *J. Biol. Chem.* 266, 24184–24189. doi: 10.1002/jbc.288314410-0

Kuge, O., Saito, K., and Nishijima, M. (1997). Cloning of a Chinese hamster ovary (CHO) cDNA encoding phosphatidylserine synthase (PSS) II, overexpression of which suppresses the phosphatidylserine biosynthetic defect of a PSS I-lacking mutant of CHO-K1 cells. *J. Biol. Chem.* 272, 19133–19139. doi: 10.1074/jbc.272.31.19133

Lehto, M., Hynynen, R., Karjalainen, K., Kuismanen, E., Hyvärinen, K., and Ollkonen, V. M. (2005). Targeting of OSBP-related protein 3 (ORP3) to endoplasmic reticulum and plasma membrane is controlled by multiple determinants. *Exp. Cell Res.* 310, 445–462. doi: 10.1016/j.yexcr.2005.08.003

Lehto, M., Laittinen, S., Chinetti, G., Johansson, M., Ehnholm, C., Staels, B., et al. (2001). The OSBP-related protein family in humans. *J. Lipid Res.* 42, 1203–1213. doi: 10.1194/jlr.M800661-JLR200

Lemmon, M. A. (2008). Membrane recognition by phospholipid-binding domains. *Nat. Rev. Mol. Cell Biol.* 9, 99–111. doi: 10.1038/nrm2328

Lenz, W. D., and Majewski, F. (1974). A generalized disorders of the connective tissues with progeria, chonalar atresia, symphalangism, hypoplasia of dentine and craniodiaphyseal hypostosis. *Birth Defects Orig. Artic Ser.* 10, 133–136.

Lev, S. (2012). Nonvesicular lipid transfer from the endoplasmic reticulum. *Cold Spring Harb. Perspect. Biol.* 4:a013300. doi: 10.1101/cshperspect.a013300

Levin, R., Hammond, G. R. V., Balla, T., De Camilli, P., Faith, G. D., and Grinstein, S. (2017). Multiphasic dynamics of phosphatidylinositol 4-phosphate during phagocytosis. *Mol. Biol. Cell* 28, 128–140. doi: 10.1091/mbc.E16-06-0451

Levine, T. P., and Munro, S. (1998). The pleckstrin homology domain of oxyester-binding protein recognises a determinant specific to Golgi membranes. *Carr. Biol.* 8, 729–739. doi: 10.1002/nr.70296-9

Levine, T. P., and Munro, S. (2002). Targeting of Golgi-specific pleckstrin homology domains involves both PtdIns 4-kinase-dependent and -independent components. *Carr. Biol.* 12, 695–704. doi: 10.1002/nr.9820(22)0.00779-0

Levin-Konigsberg, R., Montañé-Rendón, F., Keren-Kaplan, T., Li, R., Ego, B., Mylnaganam, S., et al. (2019). Phagolysosome resolution requires contacts with the endoplasmic reticulum and phosphatidylinositol-4-phosphate signalling. *Nat. Cell Biol.* 21, 1234–1247. doi: 10.1038/s41467-019-0394-2

Lim, C.-Y., Davis, O. B., Shin, H. R., Zhang, J., Berdan, C. A., Jiang, X., et al. (2016). Oxysterol-binding protein homologue ORP1L interacts with Rab7 and alters functional properties of late endocytic compartments. *Mol. Biol. Cell* 16, 5480–5492. doi: 10.1091/mbc.e05-03-0189

Liu, X., and Ridgway, N. D. (2014). Characterization of the sterol and phosphatidylinositol 4-phosphate binding properties of Golgi-associated OSBP-related protein 9 (ORP9). *PloS One* 9:e108368. doi: 10.1371/journal.pone.0108368

Lim, C.-Y., Davis, O. B., Shin, H. R., Zhang, J., Berdan, C. A., Jiang, X., et al. (2016). Oxysterol-binding protein homologue ORP1L interacts with Rab7 and alters functional properties of late endocytic compartments. *Mol. Biol. Cell* 16, 5480–5492. doi: 10.1091/mbc.e05-03-0189

Liu, X., and Ridgway, N. D. (2014). Characterization of the sterol and phosphatidylinositol 4-phosphate binding properties of Golgi-associated OSBP-related protein 9 (ORP9). *PloS One* 9:e108368. doi: 10.1371/journal.pone.0108368
Loewen, C. J. R., Roy, A., and Levine, T. P. (2003). A conserved ER targeting motif in three families of lipid binding proteins and in Opitp binds VAP. *EMBO J.* 22, 2025–2035. doi: 10.1093/emboj/cdg201

Lu, D., Sun, H. Q., Wang, H., Baryliko, B., Fukata, Y., Fukata, M., et al. (2012). Phosphatidylinositol 4-Kinase III ± is palmitoylated by golgi-localized palmitoyltransferases in cholesterol-dependent manner. *J. Biol. Chem.* 287, 21856–21865. doi: 10.1074/jbc.M112.348094

Machaca, K. (2020). Ca2+ signaling and lipid transfer “pas a deux” at ER-PM contact sites orchestrate cell migration. *Cell Calc.* 89:102226. doi: 10.1016/j.ccell.2020.102226

Maeda, K., Anand, K., Chiapparino, A., Kumar, A., Poletto, M., Kアクonen, M., et al. (2013). Interactive map uncovers phosphatidylinositol transport by oxysterol-binding proteins. *Nature* 501, 257–261. doi: 10.1038/nature12430

Manni, M., Lee, S. Y., Lucast, L., Cremona, O., Di Paolo, G., De Camilli, P., et al. (2007). The dual phosphatase activity of synaptojanin1 is required for both efficient synaptic vesicle endocytosis and reavailability at nerve terminals. *Neuron* 56, 1004–1018. doi: 10.1016/j.neuron.2007.10.032

Marat, A. L., Waltho, A., Lo, W. T., Müller, R., Norata, G. D., Falasca, M., et al. (2017). mTORC1 activity repression by late endosomal phosphatidylinositol 3,4-bisphosphate. *Science* 356, 968–972. doi: 10.1126/science.aaf8310

Mathieu, M., Martin-Jaulard, L., Lavieu, G., and Théry, C. (2019). Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication. *Nat. Cell Biol.* 21, 9–17. doi: 10.1038/s41556-018-0250-9

McGrath, M. J., Eramo, M. J., Gurung, R., Sriratana, A., Gehrig, S. M., Maeda, K., Anand, K., Chiapparino, A., Kumar, A., Poletto, M., Kaksonen, M., et al. (2012). PtdIns4P synthesis by PI4KIIIα. *J. Cell Biol.* 198, 1003ñ1016. doi: 10.1083/jcb.200510084

Mukai, K., Kido, Y., Nishimura, W., Kikuchi, M., et al. (2015). Sac2/INPP5F is an inositol 4-phosphatase that functions in the endocytic pathway. *J. Cell Biol.* 200, 373ñ383. doi: 10.1083/jcb.201212113

Murphy, S. E., and Levine, T. P. (2016). V AP, a versatile access point for lipid transport at cell contact sites with other organelles. *Nat. Publ. Group* 17, 69–82. doi: 10.1038/nrm.2015.8

Nylen, O. S., Hinck, L., Daggett, V., Yarden, Y., and Sheetz, M. P. (2007). The dual phosphatase activity of synaptojanin1 is required for both efficient synaptic vesicle endocytosis and reavailability at nerve terminals. *Neuron* 56, 1004–1018. doi: 10.1016/j.neuron.2007.10.032

Olkkonen, V. M. (2015). OSBP-related protein family in lipid transport over membrane contact sites. *Lipid Insights* 8, 1726ñ1729. doi: 10.4137/LIP.S13726

Orr, D. M., and Revzin, A. (1996). A presynaptic inositol-5-phosphatase. *Science* 270, 601ñ612. doi: 10.1126/science.aaf8310

Phillips, M. J., and Voeltz, G. K. (2015). Structure and function of ER membrane contact sites with other organelles. *Nat. Publ. Group* 17, 69–82. doi: 10.1038/nrm.2015.8

Pietrangelo, A., and Ridgway, N. D. (2018). Bridging the molecular and biological functions of the oxysterol-binding protein family. *Cell* 3, 413ñ419. doi: 10.1016/j.cell.2018.06.037

Prinz, W. A., Toomalay, A., and Balla, T. (2019). The functional universe of membrane contact sites. *Nat. Rev. Mol. Cell Biol.* 20, 1388ñ1399. doi: 10.1038/s41580-019-0180-9

Rai, A., Pathak, D., Thakur, S., Singh, S., Dubey, A. K., and Mallik, R. (2016). Dynemin clusters into lipid microdomains on phagosomes to drive rapid transport toward lysosomes. *Cell* 164, 722–734. doi: 10.1016/j.cell.2015.12.054

Rameh, L. E., Arvidsson, A. K., Carraway, K. L., Couvillon, A. D., Ratibun, G., Crompton, A., et al. (1997). A comparative analysis of the phosphoinositide-binding specificity of pleckstrin homology domains. *J. Biol. Chem.* 272, 20295ñ20266. doi: 10.1074/jbc.272.35.20259

Ramos, A. R., Ghosh, S., Suhel, T., Chevalier, C., Obeng, E. O., Fafilek, B., et al. (2020). Phosphoinositide 5-phosphatases: insights from the Lowe syndrome protein OCRL. *Trends Biochem. Sci.* 37, 134–143. doi: 10.1016/j.tibs.2012.01.002

Rao, R. S., and Willecke, K. (2011). Osmatopin1 localizes to the endoplasmic reticulum and the nucleus: an update. *Adv. Biol. Regul.* 59, 1003ñ1016. doi: 10.1016/j.abrr.2011.06.002

Reis, A. M., and Raikhel, N. V. (2015). Sterol and phospholipid microdomains in plasma membranes. *Nat. Rev. Mol. Cell Biol.* 16, 722–734. doi: 10.1038/nrm.2015.8

Rolph, S. J., and Busby, T. S. (2009). Phosphatidylinositol 4-phosphate: the nuclear localization signal for OCRL. *Lipid Insights* 2, 1ñ8. doi: 10.4137/LIP.S13726

Roth, A., Kunji, C., van der Kant, R., Janssen, L., Houben, D., Janssen, H., et al. (2009). Cholesterol sensor ORP1L contacts the ER protein V AP to control...
Rab7-RILP-p150 Glued and late endosome positioning. *J. Cell Biol.* 185, 1209–1225. doi: 10.1083/jcb.200811005

Santos, A. L., and Preta, G. (2018). Lipids in the cell: organisation regulates function. *Cell. Mol. Life Sci.* 75, 1909–1927. doi: 10.1007/s00018-017-2765-4

Santos, M. E., Rappa, G., Karbanová, J., Kurth, T., Corbell, D., and Lorico, A. (2018). VAMP-associated protein-A and oxysterol-binding protein-related protein 3 promote the entry of late endosomes into the nucleoplasmic reticulum. *J. Biol. Chem.* 293, 13834–13848. doi: 10.1074/jbc.RA118.003725

Santos, N. C., Girik, V., and Nunes-Hasler, P. (2020). ORP5 and ORP8: sterol sensors and phospholipid transfer proteins at membrane contact sites? *Biomolecules* 10:928. doi: 10.3390/biom10060928

Sasaki, J., Ishikawa, K., Arita, M., and Taniguchi, K. (2011). ACBD3-mediated recruitment of P4K2 to picornavirus RNA replication sites. *EMBO J.* 31, 754–766. doi: 10.1038/emboj.2011.429

Schiavo, G., Zilio, M., Hynynen, R., Wohlfahrt, G., Lehto, M., Johansson, M., Saarinen, S., Stoica, R., De Vos, K. J., Paillusson, S., Mueller, S., Sancho, R. M., Lau, K.-F., Scorrano, L., De Matteis, M. A., Emr, S., Giordano, F., Hajnóczky, G., Kornmann, B., et al. (2019). Coming together to define MCS sites. *Cell. Mol. Life Sci.*

van Meer, G., and de Kroon, A. I. P. M. (2011). Lipid map of the mammalian cell. *J. Cell. Sci.* 124, 5–8. doi: 10.1242/jcs.071233

van Meer, G., Voelker, D. R., and Feigenson, G. W. (2008). Membrane lipids: where they are and how they behave. *Nat. Rev. Mol. Cell Biol.* 9, 112–124. doi: 10.1038/nrm2330

van Niel, G., D'Angelo, G., and Raposo, G. (2018). Shedding light on the cell biology of extracellular vesicles. *Nat. Rev. Mol. Cell Biol.* 19, 213–228. doi: 10.1038/nrm.2017.125

Vance, J. E. (2014). Phospholipid synthesis and transport in mammalian cells. *Traffic* 16, 1–18. doi: 10.1111/tra.12230

Venditti, R., Maione, M. C., Rega, L. R., Di Tullio, G., Santoro, M., Polischuk, E., et al. (2019a). The activity of Sac1 across ER–TGN contact sites requires the four-phosphate-adapter-protein-1. *J. Cell Biol.* 218, 783–797. doi: 10.1038/sj.cjbc.201812021

Venditti, R., Rega, L. R., Maione, M. C., Santoro, M., Polischuk, E., Sarnataro, D., et al. (2019b). Molecular determinants of ER-Golgi contacts identified through a new FRET-FLIM system. *J. Cell Biol.* 218, 1055–1065. doi: 10.1038/jcb.201812020

Vihervaara, T., Uronen, R.-L., Wohlfahrt, G., Björkhem, I., Ikonen, E., and Olkkonen, V. M. (2011). Sterol binding by OSBP-related protein 1 regulates late endosome maturation and function. *Cell. Mol. Life Sci.* 68, 537–551. doi: 10.1007/s00018-010-0470-z

Wang, C., Jea-Basley, L., and Ridgway, N. D. (2002). Oxysterol-binding protein (OSBP)-related protein 4 binds 25-hydroxycholesterol and interacts with vimentin intermediate filaments. *Biochem. J.* 361, 461–472. doi: 10.1042/0264-6021:3610461

Wang, H., Sun, H. Q., Zhu, X., Zhang, L., Alabnesi, J., Levine, B., et al. (2015). CARAP's regulate PI4P-dependent autophagosome-lysosome fusion. *Proc. Natl. Acad. Sci. U.S.A.* 112, 7015–7020. doi: 10.1073/pnas.1507231112

Wang, Y. J., Wang, J., Sun, H. Q., Martinez, M., Sun, Y. X., Maia, E., et al. (2003). Phosphatidylinositol 4 phosphate regulates targeting of clathrin adaptor AP-1 complexes to the Golgi. *Cell* 114, 299–310. doi: 10.1016/s0092-8674(03)00602-2

Wong, K., ˇCopiˇc, A., and Levine, T. P. (2017). Advances on the transfer of lipids by lipid transfer proteins at membrane contact sites. *Cell. Mol. Life Sci.*

Wong, L. H., ˇCopiˇc, A., and Levine, T. P. (2017). Advances on the transfer of lipids by lipid transfer proteins. *Biomolecules* 7, 13–27. doi: 10.3390/biom7010013

Wong, L. H., Gatta, A. T., and Levine, T. P. (2019). Lipid transfer proteins: the lipid sensors and phospholipid transfer proteins at membrane contact sites? *J. Biol. Chem.* 46, 70–76. doi: 10.1016/j.jbc.201812019

Wong, K., Meyers, R., and Cantley, L. C. (1997). Subcellular locations of phosphatidylinositol 4-kinase isoforms. *J. Biol. Chem.* 272, 13236–13241. doi: 10.1074/jbc.272.20.13236

Wong, L. H., ˇCopiˇc, A., and Levine, T. P. (2017). Advances on the transfer of lipids by lipid transfer proteins. *Trends Biochem. Sci.* 42, 516–530. doi: 10.1016/j.tibs.2017.05.001

Wu, H., Carvalho, P., and Voeltz, G. K. (2018). Here, there and everywhere: the importance of ER membrane contact sites. *Science* 361, eaan5835. doi: 10.1126/science.aan5835

Wyles, J. P., Perry, R. J., and Ridgway, N. D. (2007). Characterization of the sterol-binding domain of oxysterol-binding protein (OSBP)-related protein 4 reveals a novel role in vimentin organization. *Exp. Cell Res.* 313, 1426–1437. doi: 10.1016/j.yexcr.2007.01.018

Xu, Y., Liu, Y., Ridgway, N. D., and McMaster, C. R. (2001). Novel members of the human oxysterol-binding protein family bind phospholipids and...
Nakatsu and Kawasaki

regulate vesicle transport. J. Biol. Chem. 276, 18407–18414. doi: 10.1074/jbc.M101204200

Zerial, M., and McBride, H. (2001). Rab proteins as membrane organizers. Nat. Rev. Mol. Cell Biol. 2, 107–117. doi: 10.1038/35052055

Zewe, J. P., Miller, A. M., Sangappa, S., Wills, R. C., Goulden, B. D., and Hammond, G. R. V. (2020). Probing the subcellular distribution of phosphatidylinositol reveals a surprising lack at the plasma membrane. J. Cell Biol. 219, 253–219. doi: 10.1083/jcb.201906127

Zhao, K., and Ridgway, N. D. (2017). Oxysterol-binding protein-related protein 1L regulates cholesterol egress from the endo-lysosomal system. Cell Rep. 19, 1807–1818. doi: 10.1016/j.celrep.2017.05.028

Zhao, K., Foster, J., and Ridgway, N. D. (2020). Oxysterol-binding protein-related protein 1 variants have opposing cholesterol transport activities from the endolysosomes. Mol. Biol. Cell 31, 793–802. doi: 10.1091/mbc.E19-12-0697

Zhong, W., Yi, Q., Xu, B., Li, S., Wang, T., Liu, F., et al. (2016). ORP4L is essential for T-cell acute lymphoblastic leukemia cell survival. Nat. Commun. 7, 12702–12714.

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Nakatsu and Kawasaki. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.